drugset / Trial / NCT00104845
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Phase 1
Completed
19 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.
Timeline
- Start
- 2004-09
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human gp100 plasmid DNA vaccine | Vaccine | — | Intramuscular |
| Subject | mouse gp100 plasmid DNA vaccine | Vaccine | — | Intramuscular |